Drugs / ivlv-ADA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03645460 | Jun 2024 → Dec 2026 expected | severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ivlv-ADA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03645460 ↗ |
| Route | Intravenous | “Direct intravenous injection of ivlv-ADA lentiviral vector” NCT03645460 ↗ |